Atreca to Highlight ATRC-101 Preclinical Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Atreca, Inc. (BCEL)
Last atreca, inc. earnings: 3/11 04:30 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
REDWOOD CITY, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced that it will present a poster describing preclinical evaluations of ATRC-101 at the upcoming 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019), to be held from November 6-10 in National Harbor, MD. ATRC-101 is a novel, first-in-class therapeutic candidate that targets a tumor-associated ribonucleoprotein complex, derived from a human antibody discovered by Atreca’s proprietary Immune Repertoire Capture® (IRC™) platform. The poster will describe the characterization and target of ATRC-101 and will include preclinical data highlighting ATRC-101’s robust anti-tumor activity as monotherapy and favorable safety profile. Atreca remains on track to file an Investigational New Drug (IND) application for ATRC-101 during the fourth quar
Show less
Read more
Impact Snapshot
Event Time:
BCEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCEL alerts
High impacting Atreca, Inc. news events
Weekly update
A roundup of the hottest topics
BCEL
News
- SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - BCEL, CTLT, NS, SCXPR Newswire
- Immunome: An Oncology Powerhouse In The Making [Seeking Alpha]Seeking Alpha
- Nested Therapeutics Strengthens Board of Directors with Appointment of New Chair and Directors [Yahoo! Finance]Yahoo! Finance
BCEL
Earnings
- 11/14/23 - Miss
BCEL
Sec Filings
- 4/22/24 - Form DEFM14A
- 4/17/24 - Form 4
- 4/11/24 - Form PREM14A
- BCEL's page on the SEC website